We are live on
!
Find out more
BI
BVF Inc Portfolio holdings
AUM
$3.91B
1-Year Est. Return
304.52%
This Fund
S&P 500
This Quarter
Est. Return
+38.64%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.92%
10 Year Est. Return
+28,184.58%
AUM
$2.54B
AUM Growth
+$706M
(+38%)
Cap. Flow
+$104M
Cap. Flow
% of AUM
4.08%
Top 10 Holdings %
Top 10 Hldgs %
54.04%
Holding
74
New
12
Increased
16
Reduced
23
Closed
6
Avg Time Held
6.9
quarters
Top 10 Avg Time Held
2.2
quarters
Top 20 Avg Time Held
2.8
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Olema Pharmaceuticals
OLMA
|
+$312M |
| 2 |
Amarin Corp
AMRN
|
+$46.6M |
| 3 |
4D Molecular Therapeutics
FDMT
|
+$45.7M |
| 4 |
Protagonist Therapeutics
PTGX
|
+$40.9M |
| 5 |
Ionis Pharmaceuticals
IONS
|
+$31.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SpringWorks Therapeutics
SWTX
|
+$132M |
| 2 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$87.3M |
| 3 |
Celldex Therapeutics
CLDX
|
+$45.5M |
| 4 |
Replimune Group
REPL
|
+$38.9M |
| 5 |
Xencor
XNCR
|
+$33.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.26% |
| 2 | Miscellaneous | 0.42% |
| 3 | Financials | 0.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Olema Pharmaceuticals
OLMA
$614M
| $320M | 12.6% |
+6,661,503
| New | +$312M |
2020 Q4
0 quarters
|
|
2
DELISTED
Xoma
XOMA
| $185M | 7.26% |
4,182,243
| – | – |
2016 Q4
16 quarters
|
|
3
Kymera Therapeutics
KYMR
$8.87B
| $163M | 6.42% |
2,630,658
| – | – |
2020 Q3
1 quarter
|
|
4
Relay Therapeutics
RLAY
$3.8B
| $128M | 5.02% |
3,073,147
-305,233
| -9% | -$13.8M |
2020 Q3
1 quarter
|
|
5
Revolution Medicines
RVMD
$40.4B
| $110M | 4.31% |
2,768,049
+667,000
| +32% | +$26.4M |
2020 Q1
3 quarters
|
|
6
DELISTED
Repare Therapeutics
RPTX
| $102M | 4.01% |
2,972,191
-92,543
| -3% | -$2.77M |
2020 Q2
2 quarters
|
|
7
DELISTED
Merus
MRUS
| $102M | 4% |
5,805,571
+160,000
| +3% | +$2.36M |
2018 Q1
11 quarters
|
|
8
Cytokinetics
CYTK
$8.57B
| $101M | 3.99% |
4,878,035
+1,554,984
| +47% | +$28.4M |
2020 Q3
1 quarter
|
|
|
9
Protagonist Therapeutics
PTGX
$8.96B
| $86.2M | 3.39% |
4,273,588
+1,901,300
| +80% | +$40.9M |
2017 Q4
12 quarters
|
|
|
10
Ionis Pharmaceuticals
IONS
$7.04B
| $77.1M | 3.04% |
1,364,461
+629,406
| +86% | +$31.4M |
2019 Q3
5 quarters
|
|
11
Arcus Biosciences
RCUS
$2.87B
| $71.4M | 2.81% |
2,752,222
+155,000
| +6% | +$3.75M |
2018 Q1
11 quarters
|
|
|
12
Xencor
XNCR
$1.75B
| $55.2M | 2.17% |
1,264,754
-803,344
| -39% | -$33.2M |
2020 Q1
3 quarters
|
|
13
Xenon Pharmaceuticals
XENE
$3.33B
| $53.8M | 2.12% |
3,499,346
| – | – |
2014 Q4
24 quarters
|
|
|
14
Amarin Corp
AMRN
$245M
| $52.6M | 2.07% |
538,080
+483,080
| +878% | +$46.6M |
2020 Q3
1 quarter
|
|
15
AC Immune
ACIU
$239M
| $50.8M | 2% |
9,816,658
-2,100
| -0% | -$10.7K |
2018 Q3
9 quarters
|
|
16
ALX Oncology
ALXO
$135M
| $46.6M | 1.83% |
540,837
-98,091
| -15% | -$5.9M |
2020 Q3
1 quarter
|
|
|
17
4D Molecular Therapeutics
FDMT
$683M
| $45.8M | 1.8% |
+1,106,070
| New | +$45.7M |
2020 Q4
0 quarters
|
|
18
IDEAYA Biosciences
IDYA
$3.31B
| $45.2M | 1.78% |
3,226,769
| – | – |
2019 Q2
6 quarters
|
|
19
DELISTED
ESSA Pharma
EPIX
| $44.2M | 1.74% |
3,705,289
+699,700
| +23% | +$4.93M |
2018 Q1
11 quarters
|
|
20
Spero Therapeutics
SPRO
$67M
| $43.5M | 1.71% |
2,243,278
+898,944
| +67% | +$14M |
2017 Q4
12 quarters
|
|
21
Kura Oncology
KURA
$874M
| $40.7M | 1.6% |
1,245,912
-243,200
| -16% | -$8.55M |
2017 Q3
13 quarters
|
|
22
Sutro Biopharma
STRO
$183M
| $40.3M | 1.58% |
185,416
-123,304
| -40% | -$20.4M |
2019 Q3
5 quarters
|
|
23
Lexicon Pharmaceuticals
LXRX
$716M
| $37.5M | 1.48% |
+10,963,000
| New | +$20.9M |
2020 Q4
0 quarters
|
|
|
INFI
24
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $36.9M | 1.45% |
17,426,968
| – | – |
2016 Q2
18 quarters
|
|
25
CytomX Therapeutics
CTMX
$508M
| $36.5M | 1.44% |
5,576,471
+2,016,749
| +57% | +$14.4M |
2019 Q1
7 quarters
|
|
Similar funds
LFCM
DCM
LNC
GL
AC
FFGIM
AIM
LCM
BVF Inc's Q4 2020 Portfolio in Review
As of Q4 2020, BVF Inc held 74 positions worth $2.54B, up 38% from $1.84B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
BVF Inc deployed $104M of net new capital in Q4 2020, opening 12 new positions and adding to 16 existing holdings. Its largest new stake was Olema Pharmaceuticals: 6,661,503 shares worth $320M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $132M trimmed.
- BVF Inc's largest Q4 2020 buy was Olema Pharmaceuticals: 6,661,503 shares worth $320M.
- BVF Inc added most to Amarin Corp in Q4 2020, an estimated $46.6M increase.
- BVF Inc's biggest Q4 2020 reduction was SpringWorks Therapeutics, cutting an estimated $132M.
- BVF Inc fully exited Celldex Therapeutics in Q4 2020, selling an estimated $45.5M.
- BVF Inc's ten largest holdings make up 54% of its $2.54B portfolio in Q4 2020.
- BVF Inc opened 12 new positions and closed 6 in Q4 2020.
- BVF Inc's portfolio value rose 38% quarter-over-quarter to $2.54B.
Based on BVF Inc's 13F filing for Q4 2020, filed 12 Feb 2021.